Top Markets
Coin of the day
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
Rangering i aksjer #2738
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Aksjekurs
$70.50
Sist synkronisert: 2025-11-14
Markedsverdi
$7.33B
Endring (1 dag)
0.00%
Endring (1 år)
116.32%
Land
US
Handel Metsera, Inc. (MTSR)

Kategori

Utbytteavkastning for Metsera, Inc. (MTSR)
Metsera, Inc. (aksjesymbol: MTSR) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Metsera, Inc. (MTSR) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH